Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of 4 difference direct oral anticoagulants, dabigatran, rivaroxaban, apixaban and edoxaban in real-world clinical practice: a single center prospective all-comer registry

Trial Profile

Safety and efficacy of 4 difference direct oral anticoagulants, dabigatran, rivaroxaban, apixaban and edoxaban in real-world clinical practice: a single center prospective all-comer registry

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DIRECT registry
  • Most Recent Events

    • 25 Jan 2019 Results published in the American Journal of Cardiology.
    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
    • 29 Aug 2018 Status changed from recruiting to completed, according to results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top